注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Affimed NV是一家臨床階段的生物製藥公司,致力於發現和開發癌症免疫療法。該公司開發免疫腫瘤領域的候選產品,代表一種旨在利用人體自身免疫系統對抗腫瘤細胞的癌症研究方法。其產品包括AFM13、AFM13+過繼性NK細胞、AFM13+抗PD-1、AMF24、AMF26、AMF28和AMF32。該公司正在將患者納入針對AFM13的CD30陽性複發/難治性外周T細胞淋巴瘤的定向研究,以及AFM24治療晚期EGFR表達實體瘤的1/2a劑量遞增/擴展研究。其臨床前候選產品包括用於治療多發性骨髓瘤的AMF26,以及用於治療多個腫瘤靶標的AMF28和AMF32。此外,該公司與Genentech合作,開發和商業化可治療多種癌症的候選產品。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Anton Hagenbeek | - | - | Member of Scientific Advisory Board |
Bernhard R. M. Ehmer | 69 | 2016 | Independent Member of Supervisory Board |
Miroslav S. Ravic | 75 | - | Member of Scientific Advisory Board |
Ulrich M. Grau | 75 | 2013 | Independent Member of Supervisory Board |
Ulrike Köhl | - | - | Member of Scientific Advisory Board |
Thomas O. Hecht | 73 | 2007 | Independent Chairman of Supervisory Board |
Annalisa Mary Jenkins | 59 | 2020 | Independent Member of Supervisory Board |
Christian Hucke | - | - | Member of Scientific Advisory Board |
Andreas Engert | - | - | Member of Scientific Advisory Board |
Max S. Topp | - | - | Member of Scientific Advisory Board |
Susanne Becker | - | - | Member of Scientific Advisory Board |
Franck Morschhauser | - | - | Member of Scientific Advisory Board |
Stephen M. Ansell | - | 2015 | Member of Scientific Advisory Board |
Mathieu Simon | 68 | 2018 | Independent Member of Supervisory Board |
Andrew Evens | - | 2016 | Member of Scientific Advisory Board |
Owen A. O'Connor | - | 2015 | Member of Scientific Advisory Board |
Uta Kemmerich-Keil | 58 | 2021 | Independent Member of Supervisory Board |
Constanze Ulmer-Eilfort | 61 | 2023 | Independent Member of Supervisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核